 |
인쇄하기
취소
|
HanAll to initiate Phase I study for oral human growth hormone
HanAll BioPharma said Monday that the Korea Food and Drug Administration approved the first clinical trial for oral human growth hormone (codename: HL-032).
The company plans to conduct its Phase I trial for HL-032 in the latter half of this year.
Company officials said the molecule is modified through amino acid substitutions and domain engineering, thus resulting in resistance to the ga...
The company plans to conduct its Phase I trial for HL-032 in the latter half of this year.
Company officials said the molecule is modified through amino acid substitutions and domain engineering, thus resulting in resistance to the ga...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.